Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, were presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 30 to June 3, 2008.

"The breadth of data presented at ASCO highlights the promise nimotuzumab holds for a diverse group of oncology patients," said David Allan, Chairman and CEO of YM BioSciences. "In each of these trials, results further demonstrated the unique potential for nimotuzumab to be an effective EGFR-targeting antibody without deleterious side-effects observed with the other drugs in its class."

"Phase III trial of nimotuzumab for the treatment of newly diagnosed

diffuse intrinsic pontine gliomas in children and adolescents" (Abstract

number 2058):

This poster reported data from a multi-centre Phase III study evaluating the feasibility and efficacy of nimotuzumab as the primary treatment for these patients. Between March 2006 and August 2007, 42 patients aged 3 to 16 years (median 7 years) were enrolled in this study, with 41 patients evaluable for response. The primary endpoint for the trial is median progression free survival at six months after diagnosis. Secondary endpoints include overall survival, response rate, toxicity and quality of life.

The poster presentation described preliminary results including that the median progression free survival was 5.9 months, that the median
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) ... and high prices in 2008. However, the situation has ... on gaining momentum now. , To date, the world ... 100,000 thousand tonnes. No considerable growth was registered in ... rocketed during 2012-2013, registering 11% growth as against the ...
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... March 26, 2015 PRC Clinical, a ... today several management and executive appointments effective immediately. , ... Officer (CFO) and member of the Board of Directors. ... Operations, and Sue Dowden will assume the position of ... current Chief Operations Officer (COO), has been appointed to ...
(Date:3/26/2015)... Mich., March 26, 2015 Neogen Corporation (NASDAQ: ... for the third quarter of fiscal 2015, which ended ... the prior year,s $6,575,000. Earnings per share in the ... ago. Current year-to-date net income increased 17% over prior ... $20,621,000, or $0.56 per share, for the same period ...
Breaking Biology Technology:World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ... (SFDA) has approved the,investigational new drug application (IND) for its ... This IND,approval allows Biolaxy to initiate its first phase I ... disorder characteristic of high blood glucose and poor,metabolism. The complications ...
... Primary efficacy endpoint has been met for ... , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. ... biopharmaceutical company focused on endocrine therapy and oncology, today announced ... targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with ...
... DIEGO, Nov. 24, 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... present at the Piper Jaffray 21st Annual Health Care Conference on ... Time) at the New York Palace Hotel in New York City. ... provide an overview of the company, including its clinical development and ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group ... NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one ... feedback on their experience with the Wocket in multiple scenarios ... CVS, Whole Foods and other retailers, making both debit and ... Tuttle also says, "If the company meets their plans ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Hand Geometry - Global Strategic Business Report" ... worldwide markets for Hand Geometry in US$ Thousands. The report ... , Japan , Europe ... America , and Rest of World. Annual ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... can we find out about the future dangers it poses" ... Earths climate for several hundred thousand years, complete with samples ... the lab for analysis. Incredibly, this record exists, in the ... Science Foundation programme has a key role in deciphering it. ...
... Software ... Companies, ... Corporation ("CIC"), a leading,supplier of electronic signature solutions for business process ... announced today its inclusion for the third time in Software,Magazine,s Software ...
... WASHINGTON -- If projected increases in the use of ... quality could be considerable, and water supply problems at ... a new report from the National Research Council. ... and identified opportunities for new agricultural techniques and technologies ...
Cached Biology News:European lead in reading past climates from ice cores 2European lead in reading past climates from ice cores 3CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 2CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 3Increase in ethanol production from corn could significantly impact 2Increase in ethanol production from corn could significantly impact 3
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
Request Info...
... RNase-Free DNase is a preparation of ... double-stranded DNA to produce 3-hydroxyl oligonucleotides. ... in applications where maintaining the integrity ... is qualified for use with the ...
Biology Products: